Blinatumomab, Methotrexate, Cytarabine, and Ponatinib Trial
Phase 2
90
about 10 years
18+
1 site in TX
About this study
This trial is testing how well blinatumomab, methotrexate, cytarabine, and ponatinib work in treating patients with Philadelphia chromosome-positive or BCR-ABL positive acute lymphoblastic leukemia that has returned or not responded to treatment. This treatment involves a combination of immunotherapy and chemotherapy drugs.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Blinatumomab
- 2.Take Cytarabine
- 3.Take Methotrexate
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
blinatumomab, cytarabine, methotrexate, ponatinib
injection, intravenous, injection (Injection), oral (Oral Tablet)
Primary: Event-free survival, Overall response rate (ORR) in relapsed/refractory ALL, Overall survival, Relapse-free survival
Oncology